SmithKline Beecham
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
GSK Terminates Hepatitis B Vaccine Trial Due to Efficacy Shortfalls
GSK, Hepatitis B Vaccine, Clinical Trial Termination, Efficacy Issues
GSK Advances Regulatory Filings for Linerixibat Following Successful Phase 3 Trial in PBC Itch Treatment
GSK, Linerixibat, PBC Itch, Phase 3 Trial, Regulatory Filings, Cholestatic Pruritus
GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment
GSK, Blenrep, Belantamab mafodotin, Multiple myeloma, DREAMM-7, DREAMM-8, Darzalex, Survival advantage, Regulatory challenges
GSK Enters Strategic Alliance with Vesalius Therapeutics for Parkinson’s Disease Treatments
GSK, Vesalius Therapeutics, Parkinson’s disease, neurodegenerative diseases, strategic alliance, small molecule program
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying
GSK’s Vaccine Sales Plummet in Q3, Highlighting Reduced Demand and Market Challenges
GSK, vaccine sales, third quarter, reduced demand, Arexvy, Shingrix, influenza vaccine
GSK Shifts Focus from Acquired Vaccine to Preclinical Successor Due to Increased Competition
GSK, vaccine, preclinical successor, increased competition, pneumococcal vaccine, Affinivax, MAPS technology
GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager
GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals
GSK’s Arexvy RSV Vaccine Shows Promise in Younger Adults, Following Pfizer’s Approval
GSK, Arexvy, RSV vaccine, younger adults, Pfizer, ABRYSVO, respiratory syncytial virus, lower respiratory tract disease